
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.580 | 0.920 | 0.340 |
Shares | 99.420 | 99.420 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 16.898 | 16.122 |
Price to Book | 2.679 | 2.669 |
Price to Sales | 2.233 | 2.069 |
Price to Cash Flow | 12.845 | 10.252 |
Dividend Yield | 1.285 | 2.771 |
5 Years Earnings Growth | 4.624 | 12.197 |
Number of long holdings: 97
Number of short holdings: 19
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novartis | CH0012005267 | 3.21 | 95.08 | +1.12% | |
Alnylam | US02043Q1076 | 3.14 | 306.09 | +0.50% | |
PTC Therapeutics | US69366J2006 | 3.13 | 48.83 | +0.64% | |
Astellas Pharma Inc. | JP3942400007 | 2.97 | 1,424.5 | 0.00% | |
Krystal Biotech | US5011471027 | 2.96 | 125.36 | -0.48% | |
Amgen | US0311621009 | 2.96 | 288.47 | +0.10% | |
Gilead | US3755581036 | 2.94 | 108.91 | -1.06% | |
Biomarin Pharma | US09061G1013 | 2.84 | 57.05 | -1.76% | |
Bristol-Myers Squibb | US1101221083 | 2.72 | 48.79 | +1.06% | |
Lonza Group | CH0013841017 | 2.67 | 568.60 | -0.11% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPM Global Income Fund A Mth EUR | 16.81B | -1.57 | 0.72 | - | ||
JPMorgan Global Income D div EUR | 16.81B | -1.68 | 0.38 | 1.15 | ||
JPM Global Income A acc EUR | 16.81B | -1.56 | 0.74 | 1.51 | ||
LU0740858492 | 16.81B | -1.68 | 0.38 | 1.15 | ||
JPMorgan Global Income A Div EUR | 16.81B | -1.56 | 0.74 | 1.51 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review